Sheet 1 of 5.

room PIPO	n 17449	U.S. Der	partment of C	ommerce.	ATTY. DOCKET NO		SERIAL NO	neet lo		
U.S. Department of Commerce Patent and Trademark Office				P50438-1C1		Not assigned				
NFORMATION DISCLOSURE STATEMENT				APPLICANT	· · ·		~~~	大差		
		BY APPLICA	NT		Blackburn et al.			Sign	<b>}</b>	
(Use several sheets if necessary)					FILING DATE	GROUP 6		?=		
					Herewith	Not assigned				
	7			PATENT	DOCUMENTS		8	/5		
xaminer	1	Document	Date		Name	Class	Subclass	Filing	Date	
Initial	1	Number				Ciuss		If Appr	,	
PAD	ΔΔ	5,387,681	2/7/95	Odawara, et al.		514	195			
	1	3,507,301	21173	Odawaia,	ct ar.	1314	123			
	Ц		Li			<u></u>	/			
				GN PATE	NT DOCUMENTS					
		Document Number	Date		Country	Class	Subclass	Trans		
					·	1	<del></del>	Yes	N	
PAD	AB	0 388 914 A1	9X26/90	EPO		C[2P	21/08			
				· · · · · · · · · · · · · · · · · · ·	. /			4		
		OTHER DOCU	JMENTS (In	cluding Au	thor, Title, Date Pertir	ent Page	s, Etc.)			
200	AC	Bajaj et al., "A Mo	onoclonal Aq	tibody to F	actor IX That Inhibits t	he Factor	VIII:Ca Pote	ntiation		
PAD	7.0				ol. 260, No. 21, pp. 115					
,	AD	Bajaj et al., "Antibody-Probed Conformational Transitions in the Protease Domain of Human								
- 1		Factor IX Upon Calcium Binding and Zymogen Activation: Putative High-Affinity Ca2+-Binding								
	4.55	Site in the Protease	e Domain", F	roc. Nacl.	Acad Sci., USA, Vol. 89, pp. 152-156 (1992)  Dependent Epitope to the Amino Terminal Region of the					
	AE								the	
	AF	Church et al. "An	Iuman Factor	IX , Inro	nosis Research, Vol. 8	31, No. 1,	pp. 65-73 (1	996)		
	Ar	Church et al., "An Inhibitory Monoclonal Antibody to Factor X that Blocks Prothombin Activation but not Prothrombinase Enzyme Assambly", <i>Blood</i> , Vol. 72, No. 6 (December),								
		pp. 1911-1921 (19	88)	idse Elleyli	ic Assolitory, Bloba, V	01. 72, 140	. o (Decemb	C1 <i>)</i> ,		
	AG			or XIII Lig	ht-Chain Cleavage by 7	Chrombin	and Faxtor 3	 (a".		
		Eur. J. Biochem.,	Vol. 240, pp.	<b>2</b> 65-372 (	1996)			,		
	AH Frazier et al., "Mapping of Monoclonal Antibodies to Human Factor IX", Blood, Vol. 74								-	
pp. 971-977 (1989)										
AI Fulcher et al., "Localization of Human Factor FVIII Inhibitor Epitopes to Tw							wo Polypep	ide		
Fragments", Proc. Natl. Acad. Sci. USA, Vol. 82, pp. 7728-7732 (1985)  AJ Healey et al., "Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the								<del></del>		
								e in the A	<b>A2</b>	
Domain of Human Factor VIII", J. Biol. Chem., Vol. 270, No. 24, pp. 14505-14509 (1995)  AK Hoffman et al. Factors IXa and Xa Play Distinct Roles in Tissue Factor-Dependent Initial of Coagulation", Blood, Vol. 86, No. 5, pp. 1794-1801 (1995)										
							Dependent In	itiation		
							<del>\</del>			
AL L. Hoyer and D. Scandella, "Factor VIII Inhibitors: Str										
1	AM	and Heptophilia A Patients", Seminars in Hematology, Vol. 31, No. 2, Suppl. 4, pp. 1-5 (1994)  Jenny et al., Immunochemical Techniques for Studying Coagulation Proteins", Methods in								
Enzymology, Vol. 222, pp. 400-416 (1993)								s m		
1	AN	Larson et al., "Structural Integritity of the γ-Carboxyglutamic Acid Domain of Human Blood								
Coagulation Factor IXa is Required for Its Binding to Cofactor VIIIa", J. Biol. Chem., Vol. 2								1. 271		
		No. 7, pp. 3869-38							•	
XAMIN	F/R				DATE CONSIDERE	D		1		
4	•			4/4/03			•			
	- w	A A - DURY			4/4/4				•	

Sheet 2 of 5 Form PTO-1449 U.S. Department of Commerce ATTY, DOCKET NO. SERIAL NO. Patent and Trademark Office | P50438-1C1 INFORMATION DISCLOSURE STATEMENT **APPLICANT** Blackburn et al. BY APPLICANT FILING DATE GROUP (Ose several sheets if necessary) Herewith Not assigned **U.S. PATENT DOCUMENTS** Document Examiner Date Subelass Filing Date Name Class Initial Number If Appropriate FOREIGN PATENT DOCUMENTS Document Date Country Class Subclass **Translation** Number Yes I No OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.) Leyte et al., "Inhibition of Human Coagulation Factor VIII by Monoclonal Antibodies", AO PAO J. Biochem., Vol. 263, pp. 187-194 (1989) Lollar et al., "Inhibition of Human Factor VIIIa by Anti-A2 Subunit Antibodies", J. Clin. Invest., Vol. 93, pp. 2497-2504 (1994) AQ J. Loscalzo and A. Schafer, "Factor VNI and Other Coagulation Factor Inhibitors", Thrombosis and Hemorrhage, Chapter 37, pp. 729-747 (1994) Lubin et al., "Elimination of a Major Inhibor Epitope in Factor VIII", J. Biol. Chem., Vol. 269, No. 12, pp. 8639-8641 (1994) Quellette, et al., "Neutralization of Fagor X Activity by Factor X-Specific Monoclonal Antibodies", Blood Coagulation and Fibrinolysis Vol. 3, pp. 563-574 (1992) Saenko et al., "Slowed Release of Thrombin-Cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition", J. Biol. Chem., Vol. 271, No. 44, pp. 27424-27431 (1996) D. Scandella, "Human Antibodies Which Inactivate Factor VIII: Their Epitope Specificity and Biochemical and Functional Characteristics", International Journal of Pediatric Hematology/ Oncology, Vol. T, pp. 437-447 (1994) D. Scandella, "Human Anti-Factor VIII Antibodies: Epitope Localization and Inhibitory Function", Vox Sanguinis, Vol. 70 (suppl 1), pp. 9-14 (1996) Sinha et al., "Functional Characterization of Human Blood Coagulation Factor XIa Using Hybridoma S. hngen et al., "Acquired Factor VIII Inhibitors in Nonhemophilic Patients", Ann Hematol., Vol. 74 pp. 89-93 (1997) Sugabara et al., "Isolation and Characterization of Canine Factor IX", Thrombosis, and Haemonstasis, Vol. 75(3), pp. 450-455 (1966) Plarks et al., "Factor VIII Epitopes Recognized with Inhibitory Monoclonal Antibodies", Acta Haematol, Vol. 83, pp. 69-75 (1990) **EXAMINER** DATE CONSIDERED

•EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

PATOKCIA A DUTT-1

4/4/03

Sheet 3 of 5 Form PTO-1449 SERIAL NO. U.S. Department of Commerce ATTY. DOCKET NO. Patent and Trademark Office Not assigned P50438-1C1 INFORMATION DISCLOSURE STATEMENT **APPLICANT** Blackburn et al. BY APPLICANT **GROUP** FILING DATE Not assigned (Use several sheets if necessary) July 1, 1999 U.S. PATENT DOCUMENTS **N**ocument Date Subclass Filing Date Name Class Examiner Number If Appropriate Initial FOREIGN PATENT DOCUMENTS Document Date Country Class Subclass **Translation** Number Yes No OTHER DOCUMENTS (Including Author, Title, Date, Fertinent Pages, Etc.) Abstracts, "Thrombosis and Naemostasis", J. International Society on Thrombosis and Haemostasis, BA PAD Vol. 69(6), p. 1239, Abstract 2485 (1993) Bessos et al., "The Characterization of a Panel of Monoclonal Antibodies to Human Coagulation BB Factor IX", Thrombosis Research, Vol. 40, pp. 863/867 (1985) Biedmond et al., "Complete Inhibition of Endotexin-Induced Coagulation Activation in Chimpanzees BC With a Monoclonal Fab Fragment Against Factor VII/VIIa", Thrombosis and Haemostasis, Vol. 73, No. 1, pp. 223-230 (1995) F. Desposito and Y. Arkel, "Inhibitors of Coagulation in Children", Critical Reviews in BD Oncology/Hematology, Vol. 7, No. 1, pp. 53-69 (1987) Griffin et al., "The Production and Characterisation of a Panel of Ten Murine Monoclonal Antibodies BE to Human Procoagulant Factor VIII", Thrombosis and Haemostasis, Vol. 55 (1), pp. 40-46 (1986) BF S. Morrison, "In Vitro Antibodies: Strategies for Production and Application", Annu. Rev. Immunol., Vol. 10, pp. 239-65 (1992) Warrier et al., "Safety of High Doses of a Monoclonal Antibody-Purified Factor IX Concentrate", BG American Journal of Henlatology, Vol. 49, pp. 92-94 (1995) BH Lenting et al., "A Novel Antithrombotic Strategy Based on Inhibitors of Factor VIII-Factor IX Complex Assembly, Thrombosis and Hemostasis, June Supplement, p. 689 (1997) Lenting et al., "The Sequence Glu 1811-Lys 1818 of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX", The Journal of Biological Chemistry, Vol. 271, No. 4, pp. 1935-1946 (1996) Lenting et al., "Identification of a Binding Site for Blood Coagulation Factor IXa on the Light Chain BJ of Human Factor VIII", The Journal of Biological Chemistry, Vol. 269, No. 10, pp. 7150-7155 (1994) L. Streer, Biochemistry, W.H. Freeman and Company, San Francisco, 1981, pp. BK Kasai et al., "Molecular Cloning of Murine Monoclonal Anti-idiotypic Fab", Journal of BL Immunological Methods, Vol. 155, pp. 77-89 (1992) **EXAMINER** DATE CONSIDERED PATRICIA A-DUFT-1 EXAMDER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line

through citation if not in conformance and not considered. Include copyof this form with next communication to

applicant.

Sheet 4 of 5. Form PTO-1449 U.S. Department of Commerce ATTY. DOCKET NO. SERIAL NO. Patent and Trademark Office P50438-1C1 Not assigned INFORMATION DISCLOSURE STATEMENT **APPLICANT** Blackburn et al. BY APPLICANT FILING DATE GROUP (Use several sheets if necessary) Herewith Not assigned **U.S. PATENT DOCUMENTS** Filing Date Examiner Document Subglass Date Name Class Initial Number If Appropriate FOREIGN PATENT DOCUMENTS Document Date Country Class Subclass Translation Number Yes | No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Fang et al., "Human Rheuma oid actors with Restrictive Specificity for Rabbit Immunoglobulin G: BM PAD Auto- and Multi-reactivity, Diverse ... VAIIIb", J. Exp Med., Vol. 179, pp. 1445-1456 (1994) Silberstein et al., "Relationship of Variable Region genes Expressed by a Human B Cell .... BN Autoantibodies", J. Exp. Med., Vol. 169, pp. 1631/1643 (1989) BO Pascual, et al., "The Complete Nucleonde Sequences of the Heavy Chain Regions ... Rheumatoid; Arthritis", J. Clin. Invest., Vol. 86, pp. 1320-7328 (1990) Roark, et al., "Breakdown of B Cell Tolera ce in a Mouse Model of Systemic Lupus Erythematosus", BP J. Exp. Med., Vol. 181, pp. 1157-1167 (1995) S. Stark and A. Caton, "Antibodies That Are Specific for a Single Amino Acid Interchange in a BQ Protein Epitope Use Structurally Distinct Variable Regions", J. Exp. Med., Vol. 174, pp. 613-624 (1991)Minnema et al., "Enhancement of Rabbit Jugular Vein Thrombolysis by Neutralization of Factor XI", BR J. Clin. Invest., Vol. 101, pp. 10-14 (1998) C. Granger, "Heparin Management in Acute Myocardial Infarction (AMI)", Aust NZ J Med, Vol. 28, pp. 541-547 (1998) BT Watkins et al., "Determinants of Rebound Thrombin Activity After Cessation of Heparin in Patients Undergoing Coronary Interventions", Catheterization and Cardiovascular Diagnosis, Vol. 44, pp. 257-264 (1994 BU Cannon et al., TNK-Tissue Plasminogen Activator Compared With Frant-Loaded Alteplase in Acute Myocardial Infarction", Circulation, Vol. 98, No. 25, pp. 2805-14 (1998) BV K. Tachias and E. Madison, "Variants of Tissue-type Plasminogen Activator That Display Extraordinary ... Plasminogen Activator Inhibitor Type 1", The Journal of Biological Chemistry, Vol 272, No. 23, pp. 14580-14585 (1997) Fuisse et al., "A Tissue Plasminogen Activator/P-Selectin Fusion Protein Is an Effective Phrombolytic Agent", Circulation, Vol. 95, pp. 715-722 (1997) **EXAMINER** DATE CONSIDERED

EXAMPLER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw like

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw like through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.

Sheet 5 of 5.

Form PTO-1449		1449				ATTY. DOCKET NO.		SERIAL NO.			
Patent and Trademark Office											
NFORMATION DISCLOSURE STATEMENT					APPLICANT						
\			BY APPLICAN	νT		Blackburn et al.					
						FILING DATE GROU					
		<b>\U</b> s	e several sheets if n	ecessary)		Herewith		Not assigned	d /		
		7		U.S.	PATENT	DOCUMENTS					
Exami	Examiner Document Date					Name	Class	Subclase	Filing	Date	
Initi			Number						If Appropriate		
		-									
<u> </u>	1			FOREI	CN DATE	ATT DO CHIEVENING		/			
		_	Document	Date	GN PATE	NT DOCUMENTS	Class	Subclass	Transl	otion	
	ŀ		Number	Date		Country	Class	Subciass	Yes 1	No	
	-		14dilloci V		<u> </u>		/		163	110	
		-			<u> </u>	/			ll		
						uthor, Title, Date, Pertind					
	I	ВХ	Van de Werf, et al				. <i>.</i>				
PAS			plasminogen The Assent- trial", Clinical Investigation American Heart Journal, Vol. 137, No. 5,								
		BY	pp. 786-791 (1999)  Coombs et al., "Directing Sequence-specific Proteolysis to New Targets", The Journal of								
1	1	BI				. 4323-4828 (1998)	argeis,	ine Journai	oj		
	-   1	BZ	Granger et al "Th	rombin Gen	eration In	ubition and Clinical Out	comes in	Patients	Results		
	'	UL	Granger et al., "Thrombin Generation Inhibition and Clinical Outcomes in Patients Results From the GUSTO-I Trial", JACC, Vol. 31, No. 3, pp. 597-505 (1998)								
	1	CA				poin Generation and A		fter Cessatio	n of		
						ones", Circulation, Vol.					
		CB	Bouma et al., "Fac	tor XI and F	rotection o	f the Fibrin Clot Against	Lysis -	A Role for the	ne Intrins	ic	
			Pathway of Coagu	lation in Fib	rinolysis",	Thromb Haemost., Vol.	80, pp. 2	4-27 (1998)			
		CC				Therapy with Recombin			sminogen		
			Activator, Heparin, and Aspirin Mycardial Infarction", Ann. Intern. Med., Vol. 115(4), pp. 256-								
	265 (1991)   CD   Becker et al., "Molecular Basis for the Resistance of Fibring bound Thrombin to Inactivation										
	19	CD	1			sistance of Fibria bound ry and Biology of Serpin			•	)racc	
					n. Chemisi	ry ana Biology of Strpin	s, cus., C	liucii et ai., i			
	New York, pp. 55-66 (1997)  CE Neuhaus et al., "Improved Thrombolysis in Acute Myocardial of Alteplase: Results of the rt-I APSAC Patency Study (TAPS)", JACC, Vol. 19, No. 5, pp. 885-89 (1992)								of the rt	DΛ	
									r.w.		
CF Rao et al., "Thrombolysis in Myocardial Infarction With Recombinant Tissue Plasminog								inogen	····		
Activator and Streptokinase", JACC, Vol. 11, No. 1, pp. 1-11 (1988)								<b>o-</b> ··			
CG E. Topol, "The Future of Antithrombotic and Antiplatelet Therapy for Ischemic Heart Disease							Disease",				
			American Heart J	ournal, Vol.	135, pp. Sc	66-S68 (1998)					
	[								<del></del>		
EXAN	EXAMINER				DATE CONSIDERED	)					
	PATRICIA A. DURTY			414/03		/					
EYA				nsidered wh	ether or no	t citation is in conformar	ce with	MPED 600	Draw line	ρ	
						Include copyof this form			•		
applic		7.011	m comorna	Line Hot (		copjoi tilis toti	11	-,0			
						<del></del>		<del></del>			